The venture capital company Ysios Capital, member of CATALONIA.HEALTH, participates in the Series B financing round of 135 million dollars of its investee company Adcendo.

The biopharmaceutical company AELIX Therapeutics, member of CATALONIA.HEALTH, has announced that the US biotech company Gilead Sciences, Inc. has acquired the research assets related to its therapeutic HTI vaccine against HIV.

The technology platform Gate2Brain, member of CATALONIA.HEALTH, has received the Orphan Drug Designation (ODD) from the European Medicines Agency (EMA) for its innovative product, G2B-002.  

The association has launched two internal committees this 2024, the Internal Talent Committee and the Internal Shared Value Committee, two areas on which the members had pointed out the need to work as a necessity in the health sector in Catalonia. Both were launched just before the summer and join the three that have already been active for some time: the Internal Committees on Innovation, Digital and Business Development.

The biotechnological company ADmit Therapeutics, member of CATALONIA.HEALTH, receives an accreditation from the Accreditation Committee of the College of American Pathologists (CAP), based on results of a recent on-site inspection as part of the CAP’s Accreditation Programs. 

Full house at the Hub Cambra Digital de Barcelona for the last edition of the CEO Council of 2024, with Elisabeth Stampa as a special guest. Mariona Serra, President of CATALONIA.HEALTH, gave the welcome speech at this year's fifth and last edition of these small committee meetings exclusively for CATALONIA.HEALTH members.

SMARTDIABETES, the consortium led by the start-up SocialDiabetes, a member of CATALONIA.HEALTH, will receive '1.15 million in funding by the end of 2025 from EIT Health.  

The pharmaceutical company Croda Pharma, member of CATALONIA.HEALTH, announces the launch of Super RefinedTM Poloxamer 188, an innovative bioprocessing solution developed to meet the growing demands of biopharmaceutical development.  

Germans Trias i Pujol Research Institute (IGTP), member of CATALONIA.HEALTH, announces the creation of two new spin-offs: Debios Diagnostics and HealthTech Innovations.

The advanced therapeutics company Integra Therapeutics, member of CATALONIA.HEALTH, and the Lithuanian company Caszyme have announced a license agreement for the use of Cas12I, Caszyme’s innovative nucleoases, to develop safer and more efficient gene and cell therapies.

The company INBRAIN Neuroelectronics, a member of CATALONIA.HEALTH, announces the closure of a $50 million Series B financing round. The round has been led by imec.xpand with new investors such as EIC Fund, Fond-ICO Next Tech, CDTI-Innvierte and Avançsa.

Life sciences venture capital company Asabys Partners, member of CATALONIA.HEALTH, announces the investment in the biotech company Agomab Therapeutics in a Series D financing round that reaches $89 million, along with other existing investors, and with Sanofi and Invius, which join as new investors.

The new compound AOP208, initially developed by Leukos Biotech, a spin-off of the Josep Carreras Leukemia Research Institute, both members of CATALONIA.HEALTH, has been tested for the first time in patients in the SERONCO-1 phase 1 clinical trial, to assess their safety in patients with advanced solid tumors that is being carried out at the UITM-CaixaResearch Molecular Cancer Therapy Research Unit of the Vall de Hebron Institute of Oncology (VHIO). 

The general director and co-founder of the company specialized in visual and cognitive improvement WIVI Vision, member of CATALONIA.HEALTH, Eva García, wins the Dona TIC 2024 Award in the category of entrepreneur. 

Specialists from the health and technology sector have debated the opportunities and challenges that artificial intelligence presents for the health sector as a whole: improving process efficiency and innovation in the industrial and healthcare fields.

The leading international group in the production of pharmaceutical active ingredients Moehs, member of CATALONIA.HEALTH, has signed an exclusive agreement with EUROAPI to assume the production of Metamizol, the active ingredient of the drug Nolotil, in its facilities in Spain.  

A worldwide leader in specialized diagnostics Werfen, member of CATALONIA. HEALTH, announces the finalization of a partnership agreement with Seegene Inc. Under the agreement, Seegene and Werfen will set up a NewCo in Spain, Werfen-Seegene, upon the conclusion of mandatory government approvals anticipated by the first half of 2025.

The company dedicated to personalized medicine Inbiomotion, member of CATALONIA.HEALTH, have signed an exclusive agreement to start offering the MAF Test® in Italy.

The biopharmaceutical company Oryzon Genomics, member of CATALONIA.HEALTH, announces that it has received the official record of its recent meeting of End-of-Phase II for vafidemstaten for Personality Limit Disorder (TLP) with the US Food and Drug Administration (FDA). ORYZON will begin the preparation of a complete protocol for the study of Phase III PORTICO-2 that will soon be presented to the FDA for approval.  

The UMBRELLA consortium, led by Vall d'Hebron Research Institute (VHIR), a member of CATALONIA.HEALTH, and the company Siemens Healthineers, is made up of more than 20 public and private partners whose objective is to revolutionize the entire stroke care process in Europe.